Meuwissen, M.* ; Verstraeten, A.* ; Ranza, E.* ; Iwaszkiewicz, J.* ; Bastiaansen, M.* ; Mateiu, L.* ; Nemegeer, M.* ; Meester, J.A.N.* ; Afenjar, A.* ; Amaral, M.* ; Ballhausen, D.* ; Barnett, S.* ; Barth, M.* ; Asselbergh, B.* ; Spaas, K.* ; Heeman, B.* ; Bassetti, J.* ; Blackburn, P.* ; Schaer, M.* ; Blanc, X.* ; Zoete, V.* ; Casas, K.* ; Courtin, T.* ; Doummar, D.* ; Guerry, F.* ; Keren, B.* ; Pappas, J.* ; Rabin, R.* ; Begtrup, A.* ; Shinawi, M.* ; Vulto-van Silfhout, A.T.* ; Kleefstra, T.* ; Wagner, M. ; Ziegler, A.* ; Schaefer, E.* ; Gérard, B.* ; De Bie, C.I.* ; Holwerda, S.J.B.* ; Abbot, M.A.* ; Antonarakis, S.E.* ; Loeys, B.*
Heterozygous variants in CTR9, which encodes a major component of the PAF1 complex, are associated with a neurodevelopmental disorder.
Genet. Med. 24, 1583-1591 (2022)
Purpose: CTR9 is a subunit of the PAF1 complex (PAF1C) that plays a crucial role in transcription regulation by binding CTR9 to RNA polymerase II. It is involved in transcription-coupled histone modification through promoting H3K4 and H3K36 methylation. We describe the clinical and molecular studies in 13 probands, harboring likely pathogenic CTR9 missense variants, collected through GeneMatcher. Methods: Exome sequencing was performed in all individuals. CTR9 variants were assessed through 3-dimensional modeling of the activated human transcription complex Pol II-DSIF-PAF-SPT6 and the PAF1/CTR9 complex. H3K4/H3K36 methylation analysis, mitophagy assessment based on tetramethylrhodamine ethyl ester perchlorate immunofluorescence, and RNA-sequencing in skin fibroblasts from 4 patients was performed. Results: Common clinical findings were variable degrees of intellectual disability, hypotonia, joint hyperlaxity, speech delay, coordination problems, tremor, and autism spectrum disorder. Mild dysmorphism and cardiac anomalies were less frequent. For 11 CTR9 variants, de novo occurrence was shown. Three-dimensional modeling predicted a likely disruptive effect of the variants on local CTR9 structure and protein interaction. Additional studies in fibroblasts did not unveil the downstream functional consequences of the identified variants. Conclusion: We describe a neurodevelopmental disorder caused by (mainly) de novo variants in CTR9, likely affecting PAF1C function.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Autism Spectrum Disorder ; Ctr9 ; Intellectual Disability ; Neurodevelopmental Disorder ; Paf1c
Keywords plus
Language
english
Publication Year
2022
Prepublished in Year
HGF-reported in Year
2022
ISSN (print) / ISBN
1530-0366
e-ISSN
1098-3600
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 24,
Issue: 7,
Pages: 1583-1591
Article Number: ,
Supplement: ,
Series
Publisher
Lippincott Williams & Wilkins
Publishing Place
Baltimore, Md.
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30205 - Bioengineering and Digital Health
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-503200-001
Grants
Fonds Wetenschappelijk Onderzoek
Hartstichting
European Research Council
European Commission
Marfan Foundation
Dutch Heart Foundation
Belgian Cardiac Surgery Foundation
Universiteit Antwerpen
Universitair Ziekenhuis Antwerpen
Copyright
Erfassungsdatum
2022-09-09